Lozol

(Indapamide)

ApprovedSmall molecule

Sanofi

Lozol is one of 105 small molecule programs targeting Heart Failure. It is currently in Approved.

Indications

Total Trials

Active Trials

104

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Heart FailureActive, not recruiting

Multiple SclerosisNot yet recruiting

Renal InsufficiencyCompleted

Heart FailureApproved

Active, not recruiting

Multiple SclerosisPhase 2

Not yet recruiting

Renal InsufficiencyApproved

Completed

Competition

Competitive Landscape

206 competitors in Heart Failure

#DrugCompanyPhaseTrials

Lozol

Sanofi

Approved

1 2

Bayer Aspirin

Bayer

Preclinical

2 3

Brethine

Sanofi

Preclinical

1 4

Medrol

Pfizer

Preclinical

1 5

Amidate

Pfizer

Preclinical

1 6

Activase

Zemplar

Adriamycin

Savaysa

Xifaxan

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Kidney Stone

NCT06111885

Q3 2028

Phase 2Not yet recruiting

Multiple Sclerosis

NCT07765212

Clinical

Trials by Indication[1]

Type 2 DM1 trial

A Comparison of Indapamide SR 1.5 mg With HCTZ 25 mg, in Combination With an ACE-inhibitor, in Patients With Mild to Moderate AHT and Type 2 DM

Completed·LLaborMed Pharma S.A.·Phase 4·NCT00980187·56 enrolled

Spironolactone1 trial

Spironolactone Versus Indapamide in Obese and Hypertensive Patients

Unknown status·PPeking University Third Hospital·N/A·NCT03626506·400 enrolled

Kidney Stone1 trial

Indapamide and Chlorthalidone to Reduce Urine Supersaturation for Kidney Stone Prevention

Recruiting·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT06111885·99 enrolled

Renal insufficiency1 trial

Indapamide Versus Hydrochlorothiazide in Elderly Hypertensive Patients With Renal Insufficiency

Completed·WWest China Hospital·Phase 4·NCT01172431·240 enrolled

Heart Failure1 trial

The Comparison Between Spironolactone and Indapamide Monotherapy or in Combination With Amlodipine to Reduce the Risk of Heart Failure

Unknown status·SShanghai Jiao Tong University School of Medicine·Phase 4·NCT04455178·200 enrolled

3 more indications

Blood Pressure1 trial

IDEAL Study: Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs

Completed·HHospices Civils de Lyon·Phase 4·NCT00128518·139 enrolled

Hypertension1 trial

Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

Completed· Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals·Phase 2·NCT05103332·663 enrolled

Multiple Sclerosis1 trial

Open-Label, Single-Center, Single-Arm Phase 2 Futility Trial Evaluating the Use of Oral Indapamide for Reducing Pprogression of Disability in People With Primary and Secondary Progressive Multiple Sclerosis (MS)

Not yet recruiting·EEva M.M. Strijbis·Phase 2·NCT07765212·75 enrolled

Regulatory

FDA Approval Timeline[4]

Apr 29, 1993

LOZOL

NDA NDA018538

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Indapamide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Indapamide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Indapamide. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA018538). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Sanofi

Lozol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2028

Trials by Indication[1]

Type 2 DM1 trial

Spironolactone1 trial

Kidney Stone1 trial

Renal insufficiency1 trial

Heart Failure1 trial

Blood Pressure1 trial

Hypertension1 trial

Multiple Sclerosis1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News